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1.1	Introduction
Research	and	development	of	nanotechnologies	and	manufactured	nanomaterials	is	undergoing	sustained	and	rapid	expansion	with	the	numerous	bespoke	biomedical	applications.	The	processes	that	underpin	nanomedicine
pharmacokinetics	 and	 pharmacodynamics	 are	 not	 as	 fully	 characterised	 as	 for	 conventional	 small	 molecule	 medicines,	 and	 this	 complicates	 the	 development,	 optimisation	 and	 regulatory	 evaluation	 of	 novel	 nanomaterials.


























Nanotechnologies	 have	 the	 potential	 to	 generate	 exciting	 advances	 across	 numerous	 fields	 but	 understanding	 short-,	medium-,	 and	 long-term	 safety	 is	 essential	 to	 development	 of	 nanomedicine	 applications.	 As	 for	 any
medicine,	a	 robust	understanding	of	 the	exposure-response	relationship	 is	needed	along	with	a	 thorough	understanding	of	 the	 likely	plasma	and	 tissue	exposure	 in	patients.	Consequently,	understanding	 the	 interactions	between
nanomaterials	and	 the	human	body	 is	essential	 for	efficient	development	of	safe	and	effective	applications	 in	medicine.	The	 investigation	of	nanomedicine	distribution	 is	based	on	a	variety	of	experimental	methods	and	emerging
computer-based	 approaches	 have	 been	 highlighted	 as	 effective	 tools	 to	 streamline	 the	 development	 of	 innovative	 formulations.	 Computational	 models	 to	 simulate	 the	 interaction	 with	 biological	 systems	 represent	 valuable







The	 majority	 of	 currently	 clinically	 used	 nanomedicines	 involve	 the	 use	 of	 SDNs	 [8].	 SDNs	 can	 be	 produced	 using	 a	 variety	 of	 approaches	 including	 emulsion-based	 methods,	 nanoprecipitation	 [9],	 or	 high-pressure





















Once	absorbed,	drug	distribution	 in	 tissues	and	organs	 is	 simulated	 considering	 regional	blood	and	 lymphatic	 flows,	 transporter	 activity	 and	drug	physicochemical	properties	 influencing	 tissue	 to	plasma	 ratio.	Processes
mediating	drug	degradation	and	elimination	in	tissues	such	as	the	liver	and	kidney	can	be	investigated	in	vitro	through	standardised	approaches	to	provide	an	estimate	of	apparent	clearance,	which	following	integration	with	data	on












PBPK	models	 have	 relevant	 limitations	 and	 a	 full	 understanding	 of	 these	 implications	 is	 critical	 to	meaningful	 application	 of	 this	 computational	 approach.	 The	 reliability	 of	 PBPK	models	 is	 strictly	 related	 to	 a	 detailed












The	application	of	QSAR	to	pharmacokinetics	provides	 the	opportunity	 to	estimate	key	paramenters	 for	 the	prediction	of	distribution	 (Volume	of	distribution,	systemic	clearance,	protein	binding,	etc.)	and	 the	 integration	of	QSAR
models	into	a	PBPK	framework	supporting	the	simulation	of	pharmacokinetic	profiles	for	candidate	drugs	and	therefore	allowing	the	selection	of	candidates	with	optimal	pharmacokinetic	potential.	It	is	important	to	recognise	that	such




























drug	 candidate	 for	 future	 development	 is	 extremely	 complex.	 Recently,	 the	 authors	 reported	 use	 of	 a	 PBPK	 model	 to	 simulate	 theoretical	 pharmacokinetics	 resulting	 from	 LAI	 administration	 of	 experimental	 and	 established
antiretroviral	drugs	to	identify	suitable	API	candidates	and	prerequisite	formulation	behaviours	[14].




















one	 thousand	 companies	 are	 currently	 developing	 nanotechnology	 applications	 in	 medicine	 and	 consequently	 had,	 are	 or	 will	 use	 preclinical	 animal	 models	 to	 investigate	 nanoparticle	 pharmacokinetics	 and	 distribution.	 More
widespread	application	of	predictive	PBPK	modelling	in	this	type	of	investigation	has	the	potential	to	support	a	more	informed	selection	of	which	species	to	study	as	well	as	an	effective	quantification	of	animals	needed	to	achieve
sufficient	 accuracy.	 Therefore,	 PBPK	modelling	 has	 the	 potential	 to	 greatly	 reduce	 the	 overall	 number	 of	 animals	 used	 in	 nanomedicine	 development.	 Computational	 approaches	 provide	 a	 quantitative	 prediction	 of	 nanoparticle












broad	range	of	 in	vitro	and	in	vivo	data.	Frequently,	SDN	synthesis	generates	a	high	number	of	potential	candidates	and	the	direct	testing	of	all	nanoparticles	 in	vivo	would	have	multiple	ethical	and	 logistical	barriers.	A	detailed
understanding	of	the	processes	underpinning	SDN	pharmacology	combined	with	well	characterised	in	vitro	data	and	predictive	computational	models,	will	allow	a	rational	selection	of	valuable	formulations	so	that	those	without	value
can	be	killed	early	in	development.	Integrated	approaches	in	silico,	in	vitro	and	pre-clinical	in	vivo	methodologies	will	enhance	essential	knowledge	of	SDN	pharmacology	while	defining	an	optimal	framework	for	the	identification	of
nanoformulations	with	higher	pharmacological	potential.
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